SCNX: Rapid revenue growth and FDA-approved launches highlight a strong specialty pharma pipeline
Focused on innovative specialty pharmaceuticals, the company has launched FDA-approved Arbli™ and Rezenopy®, with a robust pipeline targeting CNS, cardiovascular, and pain markets. Strong IP, experienced leadership, and rapid revenue growth underscore its strategic execution.Original document: Scie…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.